<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980421</url>
  </required_header>
  <id_info>
    <org_study_id>RHN/NTF/82008-09</org_study_id>
    <nct_id>NCT00980421</nct_id>
  </id_info>
  <brief_title>Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children</brief_title>
  <official_title>Effect of Mode of Delivery of Iron and/or Iron and Zinc Supplement on Iron Status Markers and Potential Markers of Iron Toxicity in Children Aged 24-36 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annamalai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annamalai University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study is to evaluate and compare the effect of iron supplementation when given
      as iron tablet or fortified biscuit or combined with zinc in the form of tablet on morbidity
      and iron toxicity markers among children aged 24-36 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be carried out in two phases in Sangam Vihar, Delhi. The survey will be
      conducted to identify children in the age group of 24-36 months. After obtaining consent, an
      enrollment form with detailed socio-demographic information about the child will be filled.
      Blood and urine samples will be collected for estimation of iron status, oxidative stress,
      immune and interleukin markers. Based on iron status, two randomization lists will be
      generated i.e. one for iron sufficient and other for iron deficient children. Children will
      be randomly allocated to receive one of the four interventions (60 in each group) for 180
      days. The intervention will be either Iron Tablets (IT) or Iron and Zinc tablets (IZ) or
      Biscuits fortified with Iron (IB), or Placebo tablets (CO). Children in the iron groups (IT
      and IB) will receive 12.5 mg/day of iron. Children allocated to receive Iron and Zinc (IZ
      group) will receive 10 mg/day of Zinc in addition to 12.5 mg/day of Iron. The fortified
      biscuits (IB) will be formulated by CFTRI, Mysore, India and will have iron in the form of
      iron sulphate. The iron (IT group) or iron and zinc (IZ group) fortified dispersible tablets
      will be procured from WHO manufactured by Nutriset (Maluanlay, France). Tablets will have
      iron salt in the form of ferrous sulphate and zinc in the form of zinc sulphate. The
      interventions at the baseline on Day 3, on Day 30 (on completion of Phase -I) and on Day 180
      (on completion of Phase-II) will be given at the clinic prior to the post 3 hour blood
      collection. Regular supplementation will be given at home. Children will be followed up on a
      biweekly basis by the field worker for delivery of the intervention, collection of morbidity
      and compliance information from the mother/caretaker of the child. During follow-up, blood
      sample for interleukin levels will be taken in the event of an illness such as diarrhea,
      pneumonia, fever and severe illness/hospitalization. At the completion of Phase-I (on day 30)
      and Phase - II (on day 180), the blood and urine samples will be collected again for
      estimation of iron status, oxidative stress, immune and interleukin markers.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of intervention on immune response, iron over load, oxidative stress markers and iron status</measure>
    <time_frame>0 month, 1 month and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Outcome Measures: Mortality Incidence of disease requiring hospitalization interleukin response during severe illness or hospitalization</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Iron Overload</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>IT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron Tablet group (12.5 mg/d) + Placebo Biscuit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Tablet + Placebo Biscuit</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Iron Supplementation</intervention_name>
    <description>Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit</description>
    <arm_group_label>IT</arm_group_label>
    <arm_group_label>IZ</arm_group_label>
    <arm_group_label>IB</arm_group_label>
    <arm_group_label>CO</arm_group_label>
    <other_name>Ferrous sulphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 24-36 months of age

          -  not severely malnourished or ill requiring hospitalization

          -  willing to stay in the study area for 6 months

          -  consent to participate

        Exclusion Criteria:

          -  not consented

          -  severely malnourished or ill requiring hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Venugopal P Menon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Annamalai University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Venugopal P Menon, PhD</last_name>
    <phone>91-4144-238343</phone>
    <email>biocmr@sify.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jitender Kumar, PhD</last_name>
    <phone>91-41724901</phone>
    <email>cmrdelhi@airtelmail.in</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Micronutrient Research</name>
      <address>
        <city>Delhi</city>
        <zip>110024</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Venugopal P Menon, PhD</last_name>
      <phone>91-4144-238343</phone>
      <email>biocmr@sify.com</email>
    </contact>
    <contact_backup>
      <last_name>Jitendra Kumar, PhD</last_name>
      <phone>91-41724901</phone>
      <email>cmrdelhi@airtelmail.in</email>
    </contact_backup>
    <investigator>
      <last_name>Venugopal P Menon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Hoppe M, Hulth√©n L, Hallberg L. The relative bioavailability in humans of elemental iron powders for use in food fortification. Eur J Nutr. 2006 Feb;45(1):37-44. Epub 2005 Apr 25.</citation>
    <PMID>15864409</PMID>
  </reference>
  <reference>
    <citation>Olynyk JK, Clarke SL. Iron overload impairs pro-inflammatory cytokine responses by Kupffer cells. J Gastroenterol Hepatol. 2001 Apr;16(4):438-44.</citation>
    <PMID>11354283</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>September 18, 2009</last_update_submitted>
  <last_update_submitted_qc>September 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Venugopal P Menon</name_title>
    <organization>Department of Biochemistry and Biotechnology</organization>
  </responsible_party>
  <keyword>iron</keyword>
  <keyword>iron toxicity markers</keyword>
  <keyword>oxidative stress markers</keyword>
  <keyword>iron supplementation</keyword>
  <keyword>NTBI</keyword>
  <keyword>iron over load</keyword>
  <keyword>interleukin levels</keyword>
  <keyword>iron status</keyword>
  <keyword>acut phase reactants</keyword>
  <keyword>preschool children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

